Mineralys Begin Period Cash Flow from 2010 to 2025

MLYS Stock   10.36  0.44  4.44%   
Mineralys Therapeutics, Begin Period Cash Flow yearly trend continues to be comparatively stable with very little volatility. Begin Period Cash Flow will likely drop to about 32.8 M in 2025. Begin Period Cash Flow is the amount of cash Mineralys Therapeutics, Common has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities. View All Fundamentals
 
Begin Period Cash Flow  
First Reported
2010-12-31
Previous Quarter
49.3 M
Current Value
32.8 M
Quarterly Volatility
24.8 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Mineralys Therapeutics, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Mineralys Therapeutics,'s main balance sheet or income statement drivers, such as Net Interest Income of 15.3 M, Depreciation And Amortization of 143.6 K or Interest Expense of 2 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 3.28. Mineralys financial statements analysis is a perfect complement when working with Mineralys Therapeutics, Valuation or Volatility modules.
  
Check out the analysis of Mineralys Therapeutics, Correlation against competitors.

Latest Mineralys Therapeutics,'s Begin Period Cash Flow Growth Pattern

Below is the plot of the Begin Period Cash Flow of Mineralys Therapeutics, Common over the last few years. It is the amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities. Mineralys Therapeutics,'s Begin Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Mineralys Therapeutics,'s overall financial position and show how it may be relating to other accounts over time.
Begin Period Cash Flow10 Years Trend
Slightly volatile
   Begin Period Cash Flow   
       Timeline  

Mineralys Begin Period Cash Flow Regression Statistics

Arithmetic Mean11,396,498
Geometric Mean281,203
Coefficient Of Variation217.74
Mean Deviation16,952,683
Median42,000
Standard Deviation24,814,218
Sample Variance615.7T
Range87.7M
R-Value0.62
Mean Square Error405.2T
R-Squared0.39
Significance0.01
Slope3,237,152
Total Sum of Squares9236.2T

Mineralys Begin Period Cash Flow History

202532.8 M
202449.3 M
202387.7 M
202210.7 M
20211.4 M

About Mineralys Therapeutics, Financial Statements

Mineralys Therapeutics, shareholders use historical fundamental indicators, such as Begin Period Cash Flow, to determine how well the company is positioned to perform in the future. Although Mineralys Therapeutics, investors may analyze each financial statement separately, they are all interrelated. The changes in Mineralys Therapeutics,'s assets and liabilities, for example, are also reflected in the revenues and expenses on on Mineralys Therapeutics,'s income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Begin Period Cash Flow49.3 M32.8 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Mineralys Stock Analysis

When running Mineralys Therapeutics,'s price analysis, check to measure Mineralys Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mineralys Therapeutics, is operating at the current time. Most of Mineralys Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Mineralys Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mineralys Therapeutics,'s price. Additionally, you may evaluate how the addition of Mineralys Therapeutics, to your portfolios can decrease your overall portfolio volatility.